Snapshot
Danaher Corp /De/ reported $6.05B of revenue in Q3 2025, up 4.4% year over year, with diluted EPS of $1.27 and an operating margin of 19.1%.
- Revenue
- $6.05B
- YoY growth
- +4.4%
- Diluted EPS
- $1.27
- Operating margin
- 19.1%
What management said
- •We continued to see a modest recovery in pharma R&D spending, though it remains below historical levels in academic and government demand was stable sequentially but remained soft amid ongoing uncertainty around research funding.
- •Sales were $6.1 billion in the third quarter and we delivered 3% core revenue growth.
- •Core revenues in high growth markets were up low single digits as solid performance outside of China was offset by a mid single digit decline in China.
- •Growth in our biotechnology and life sciences businesses in China was more than offset by declines in diagnostics due to volume based procurement and reimbursement policy changes implemented in the last 12 months.
- •Adjusted diluted net earnings per common share of $1.89 were up approximately 10% year-over-year.
- •During the quarter, we deployed approximately $2 billion of capital towards the repurchase of 10 million shares of Danaher common stock.
- •In biotechnology, Cytiva launched the ÄKTA readyflux TFF system 500, a fully automated benchtop tangential flow filtration system developed to meet growing demand for efficient low volume processing.
- •Core revenue in discovery and medical grew low single digits in the quarter.
- •Growth in medical and lab filtration was partially offset by declines in protein research instrumentation, where academic research customers continue to face funding constraints.
- •Core revenue in bioprocessing grew high single digits with double digit growth in consumables partially offset by declines in equipment.
- •Consumables growth was driven by robust demand for commercialized therapies at our large pharma and CDMO customers.
- •Equipment revenue grew sequentially but declined in the high teens versus prior year as expected.
What went well
- •Third quarter results exceeded revenue, earnings and cash flow expectations, with sales of $6.1 billion and 3% core revenue growth driven by DBS execution, continued bioprocessing momentum and better than expected respiratory revenue at Cepheid.
- •Bioprocessing core revenue grew high single digits, with double digit consumables growth driven by robust demand for commercialized therapies at large pharma and CDMO customers.
- •Biotechnology segment core revenue increased 6.5%, and adjusted operating profit margin of 27.9% expanded 40 basis points year over year on higher volume leverage and disciplined cost management.
- •Adjusted diluted earnings per share of $1.89 rose approximately 10% year over year.
- •The company generated $1.4 billion of free cash flow in the quarter and $3.5 billion year to date, a 146% free cash flow to net income conversion ratio, while deploying about $2 billion to repurchase 10 million shares and authorizing a new 35 million share buyback program.
- •Substantial innovation investment yielded several product launches, including Cytiva's AKTA readyflux TFF system 500, IDT's high purity customizable guide RNAs, and Beckman Coulter's Access BD-Tau assay.
What went wrong
- •Bioprocessing equipment revenue declined in the high teens versus prior year, as customers awaited clarity on the policy environment before finalizing investment decisions, with cautious equipment spending expected through the rest of the year.
- •High growth markets grew only low single digits as solid performance outside China was offset by a mid single digit decline in China, driven by diagnostics declines from volume based procurement and reimbursement policy changes.
- •Life sciences end markets did not inflect, with declines in protein research instrumentation as academic and government research customers continued to face funding constraints.
- •Discovery and medical core revenue grew only low single digits, with the protein discovery business facing the same end market pressures as life science tools.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Core revenue growth | FY2026 | — | 3%-6% (anchor at low end of range to start) | Initial directional framework |
| Adjusted EPS growth | FY2026 | — | High single digit | Initial directional framework |
| Operating margin expansion | FY2026 | — | North of 100 basis points | Initial directional framework |
| Biotechnology core growth | FY2026 | — | High single digit | New planning assumption |
| Bioprocessing equipment | FY2026 | — | Assumed flat | New planning assumption |
| Respiratory revenue (Cepheid) | FY2026 | — | ~$1.7 billion (flat, endemic rate) | New planning assumption |
| China diagnostics headwind | FY2026 | — | ~$75M-$100M headwind | New planning assumption |
| Cost actions | FY2025 | — | $175M total ($150M in Q4); net $75M savings, not repeating in 2026 | New |
| Bioprocessing core growth | Q4 2025 | — | High single digits | New |
| Discovery & medical core growth | Q4 2025 | — | Down mid single digits | New |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total sales / core revenue | 3% core growth ($6.1B sales) | DBS execution, bioprocessing momentum and better than expected Cepheid respiratory revenue. |
| Biotechnology core revenue | +6.5% | High single digit bioprocessing growth with double digit consumables, partly offset by high-teens equipment decline and low single digit discovery and medical growth. |
| Bioprocessing consumables | Double digit growth | Robust demand for commercialized therapies at large pharma and CDMO customers. |
| Bioprocessing equipment | Down high teens | Customers awaiting policy clarity before finalizing investment decisions despite healthy project pipelines. |
| Adjusted operating profit margin | 27.9%, up 40 bps | Higher volume leverage and disciplined cost management more than offset productivity investments. |
| Adjusted diluted EPS | $1.89, up ~10% | Revenue beat and margin expansion. |
| China high growth markets | Mid single digit decline | Biotechnology and life sciences growth offset by diagnostics declines from volume based procurement and reimbursement policy changes. |
| Developed markets core revenue | Up mid single digits | North America up mid single digits; Western Europe approximately flat. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing equipment recovery / reshoring | — | Activity, quotations and confidence rising on brownfield investments as tariffs become planable and MFN deals turn workable, but not yet converting to orders; potential extended capital cycle over coming years | rising |
| Monoclonal antibody demand | — | Remains robust; ~75% of bioprocessing tied to mAbs, driven by growing commercial volumes, new indications and upcoming biosimilars | steady |
| China diagnostics VBP and reimbursement | — | Anniversarying the wave that began in Q4; ~$75M-$100M residual 2026 headwind viewed as modest and manageable | declining |
| China localization policy | — | 20% pricing benefit for local manufacturers; most diagnostics equipment and reagents to be localized by year end, viewed as advantageous | steady |
| Life sciences / academic and government funding | — | Modest pharma R&D recovery below historical levels; academic and government soft amid funding uncertainty; planning for flat 2026 | steady |
| Cost actions and productivity investments | — | $175M of 2025 cost actions yielding $250M net 2026 savings and ~$0.30 EPS tailwind, supporting margin expansion | rising |
| Capital deployment (M&A vs buybacks) | — | Strong bias to M&A under valuation framework; not opposed to buybacks at current levels; new 35 million share authorization | steady |
Q&A summary
What gets Danaher to the 3%-6% FY2026 core growth range, and what distinguishes a 3% year from a 6% year? (Michael Ryskin, Bank of America)
Management assumes modest end market recovery: biotechnology high single digit with strong bioprocessing consumables and flat equipment, life sciences not improving meaningfully, diagnostics accelerating past China headwinds, and respiratory flat at ~$1.7B. Matt McGrew said to anchor at the low end initially, with 35%-40% fall-through plus cost actions yielding north of 100 bps margin expansion and high single digit EPS growth even at the low end, before any capital deployment.
How de-risked is China diagnostics VBP for 2026 given concerns about another wave? (Michael Ryskin, Bank of America)
Danaher is reaching the other side of the wave that began in Q4 and will anniversary it; the 2026 assumption is roughly $75M-$100M of headwind, which is modest and manageable at the Danaher level given visibility into announced and upcoming changes.
What would it take to call a bioprocessing equipment recovery, and could equipment pick up in 2026? (Tycho Peterson, Jefferies)
Manufacturing volumes and the general need to invest are rising, and confidence is improving as MFN negotiations reach workable solutions and tariffs stabilize; activity and quotations are increasing, especially for brownfield projects, but have not yet turned into orders, so for planning purposes equipment is assumed flat. Q4 bioprocessing is high single digits.
Has activity or customer tone changed since the Pfizer MFN announcement, and is it reflected in guidance? (Doug Schenkel, Wolfe Research)
Yes, there is more confidence among pharma executives that the policy environment is finding balance and overhangs are dissipating, but Danaher has not reflected this in Q4 or initial 2026 guidance because it wants to see the improved tone convert into demonstrated order patterns first.
Why does Q4 diagnostics ex-respiratory, ex-China imply an uptick to double digits versus mid singles in prior quarters? (Vijay Kumar, Evercore ISI)
The uptick comes from lapping China VBP and reimbursement, not from the base business; the core base business remains mid single digit, while the China comparison improves in Q4 as the company anniversaries the first reimbursement hit.
What were bioprocessing order growth and book-to-bill in the quarter, and what underpins confidence in high single digit growth? (Puneet Souda, Leerink Partners)
Book-to-bill was around one, similar to the rest of the year. Confidence rests on monoclonal antibodies, about 75% of the business, growing on rising commercial volumes, new indications for on-market drugs and upcoming biosimilars, which offsets volatility in other modalities like nucleic acid therapies that will take time to reach standard of care.